Experienced in Hemoglobin SC Disease
Experienced in Hemoglobin SC Disease
160 E 32nd St, Second Floor, 
New York, NY 

Overview

Teena Bhatla is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Bhatla is rated as an Experienced provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Sickle Cell Disease, and Adult Soft Tissue Sarcoma.

Her clinical research consists of co-authoring 28 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

160 E 32nd St, Second Floor, New York, NY 10016

Additional Areas of Focus

Dr. Bhatla has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


20 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
View 19 Less Clinical Trials
Similar Doctors
Distinguished in Hemoglobin SC Disease
Pediatric Hematology Oncology
Distinguished in Hemoglobin SC Disease
Pediatric Hematology Oncology
New Hyde Park, NY 
 (15.7 miles away)
Languages Spoken:
English

Banu Aygun is a Pediatric Hematologist Oncology provider in New Hyde Park, New York. Dr. Aygun is rated as an Elite provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy.

Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
10 Nathan D Perlman Pl, 16th St At 1st Ave, 
New York, NY 
 (0.8 miles away)
Languages Spoken:
English

Yaoping Zhang is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Zhang is rated as an Advanced provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Febrile Neutropenia, Thalassemia, and Splenectomy.

Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology

Amboy Medical Practice, P.C.

800 Castleton Ave, 
Staten Island, NY 
 (10.2 miles away)
Experience:
43+ years
Languages Spoken:
English

Mario Peichev is a Pediatric Hematologist Oncology provider in Staten Island, New York. Dr. Peichev has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, and Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhatla's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile